Dispatch Biotherapeutics Is a Biotech Start-up with Penn Medicine Roots

Research from a lab at Penn Medicine has led to a new startup, Dispatch Bio, with the ambitious goal of developing a universal treatment option for solid tumors, such as lung and colon cancer. CAR T cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy, is one of the company’s scientific co-founders, and the University of Pennsylvania is an investor. 45 of its 60 employees are based in Philadelphia.